These two medicines are compared constantly for hair loss, but they are not licensed for the same thing. Finasteride, as Propecia, is indicated for the treatment of male pattern hair loss in men only. Dutasteride, as Avodart, is indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. Hair loss is not on the dutasteride label.

That single fact reframes the whole comparison, and it is missing from most articles that make it. A comparison between a licensed treatment and an unlicensed use is a legitimate thing to discuss, but only if it says that is what it is.

Key takeaways

  • Both are 5-alpha-reductase inhibitors, which is why they get compared.
  • Only finasteride is licensed for hair loss, and in men only.
  • Dutasteride is licensed for symptomatic benign prostatic hyperplasia, to improve symptoms in men with an enlarged prostate.
  • Dutasteride’s label carries a warning finasteride’s does not: it may increase the risk of high-grade prostate cancer.
  • Neither is approved for preventing prostate cancer. Dutasteride’s label states this as an explicit limitation of use.
  • Both affect PSA results, so any doctor testing your PSA must know you take one.
  • Both carry pregnancy restrictions, and dutasteride’s extends to handling the capsules at all.
  • Using an unlicensed option is a clinical decision, made with a doctor who knows your history, not a self-directed upgrade.

What is each one actually approved to treat?

Different conditions, and the labels are explicit.

Finasteride (Propecia). The label states it is “a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY”, and adds that it “is not indicated for use in women”. The emphasis on men only is the label’s own.

Dutasteride (Avodart). The label states it is “a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate” to improve symptoms. Its stated purpose is the prostate, not the scalp.

Finasteride is also used at a higher strength for enlarged prostate, which is why the same ingredient appears in two different products at two different strengths. That is worth knowing if you are matching a prescription across countries: the strength tells you which use it was prescribed for.

Why do people compare them for hair loss at all?

Because they work on the same enzyme, and there is published interest in whether the broader one performs better.

Both block 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone, and DHT is central to male pattern hair loss. The reasoning that dutasteride might therefore do more for hair is not absurd, and it is why the comparison recurs.

But the reasoning is not the same as an approval. A medicine reaches its licensed indication by demonstrating benefit and an acceptable risk balance for that specific use, in a review by a regulator. Dutasteride has done that for enlarged prostate. Where it is used for hair loss, that is an off-label decision, and the honest framing is that a doctor is choosing to accept a risk profile that was assessed against a different purpose.

Any article that presents this as simply “the stronger option” has skipped the part that matters.

What is the risk difference?

The dutasteride label carries a prostate cancer statement that the finasteride hair-loss label does not.

Two statements from the Avodart label:

  • “AVODART may increase the risk of high-grade prostate cancer.”
  • “Limitations of Use: AVODART is not approved for the prevention of prostate cancer.”

High-grade prostate cancer is the more aggressive form. That warning sits on the label of the medicine being proposed as the more powerful hair-loss option, and it is precisely the sort of thing that gets left out of an article whose sources are hair clinics.

This is not a reason to refuse dutasteride if you have been prescribed it for an enlarged prostate, where the benefit was assessed against exactly this risk. It is a reason to have the conversation explicitly if it is being considered for cosmetic use.

What do they both do to PSA testing?

Both lower it, which can make a prostate cancer screening result look better than it is.

The finasteride label states that it causes a decrease in serum PSA levels, and that any confirmed increase in PSA while on treatment may signal the presence of prostate cancer and should be evaluated, even if the value is still within the normal range for men not taking a 5-alpha-reductase inhibitor. The dutasteride label makes the same point in the same terms.

The practical rule is simple and important: tell any doctor arranging a PSA test that you take one of these. A rising PSA on treatment is meaningful even when the absolute number looks normal, and the interpretation depends on the doctor knowing.

What about pregnancy and handling?

Both restrict it, and dutasteride restricts it further.

  • Finasteride: women should not handle crushed or broken tablets when pregnant or potentially pregnant, due to potential risk to a male fetus.
  • Dutasteride: use is contraindicated in women who are pregnant, and women who are or may be pregnant should not handle the capsules at all.

The difference is meaningful in a shared household. An intact finasteride tablet is not the concern; a broken one is. A dutasteride capsule is a concern regardless. Store accordingly.

So which should I take?

That is a prescriber’s decision, and the starting point is what you are treating.

The framing that actually helps:

  • If you are treating male pattern hair loss, finasteride is the option licensed for it, with the evidence assessed for that use.
  • If you are treating an enlarged prostate, both are used, and dutasteride is licensed for it.
  • If dutasteride is being suggested for hair loss, ask directly whether it is being used off-label, why it is preferred over the licensed option in your case, and how the high-grade prostate cancer statement applies to you.

The general principle worth carrying: more potent is not the same as better. It means a larger effect on the same system, in both directions.

Do and don’t

Do:

  • Establish what you are treating before comparing medicines.
  • Ask whether a proposed use is on-label or off-label.
  • Tell any doctor testing your PSA that you take one of these.
  • Store both away from anyone who is or may be pregnant.
  • Ask what happens when you stop, since neither is curative.

Don’t:

  • Don’t assume the more potent medicine is the better choice.
  • Don’t treat a hair clinic’s comparison as a clinical assessment.
  • Don’t switch between them yourself.
  • Don’t read a normal PSA on treatment as automatic reassurance.

Frequently asked questions

Is dutasteride simply a stronger finasteride? They act on the same enzyme system with different profiles, but the difference that matters for a decision is not potency. It is that they hold different licensed indications and carry different label warnings. Potency without an approved indication for your condition is not an advantage.

Can women take either for hair loss? No. Finasteride’s label states it is not indicated for use in women, and dutasteride is contraindicated in pregnancy with handling restrictions attached. Female pattern hair loss is treated through a different route after a different assessment.

If I stop, do I keep the hair? No. Neither addresses the underlying process, so the benefit reverses after stopping. That is true of both and is the main long-term cost of either.

Where to go next

The broader picture, including non-drug options and why a diagnosis should come first, is in hair loss treatment. The hair loss and prostate health categories list what is stocked here, since these two medicines sit across both.

MedicForce option: our listings show active ingredient and strength, which is what distinguishes the hair-loss product from the prostate one for the same ingredient.

Label statements quoted above are from the approved product information for Propecia (finasteride) and Avodart (dutasteride).